RxDoctor Payments Data

Shyamala Kumar, MD

Neurology · Glendale, AZNPI 1457314841

Payments from drug & device makers

$15,360in general payments, 2019–2025

Across 766 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • AbbVie$1K
  • Biogen$1K
  • SK Life Science, Inc.$1K
  • Novartis$1K
  • AstraZeneca$990
  • plus $8K from 52 others

What the payments were for

  • Consulting fees$1751%
  • Speaking & faculty fees$720%
  • Food & beverage$15,00098%
  • Education$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.88$1,595
AbbVie(2 entities)100$1,440
Biogen65$1,339
SK Life Science, Inc.42$1,130
Novartis49$1,078
AstraZeneca32$990
Teva Pharmaceuticals USA, Inc.41$666
Pfizer28$585
Lilly USA, LLC27$475
Argenx US, Inc.21$449
Neurelis, Inc.17$420
Amneal Pharmaceuticals LLC22$378
Eisai Inc.12$355
Bristol Myers Squibb19$350
Neurocrine Biosciences, Inc.16$346
Acadia Pharmaceuticals Inc17$298
Genentech USA, Inc.15$286
Sunovion Pharmaceuticals Inc.14$251
Amgen(2 entities)13$242
Lundbeck LLC12$228
Sanofi11$202
Jazz Pharmaceuticals Inc.7$182
EMD Serono, Inc.10$174
E.r. Squibb & Sons, L.L.C.2$141
TG Therapeutics, Inc.5$136
Supernus Pharmaceuticals, Inc.8$114
Neuropace, Inc.1$109
Corium, LLC7$106
Otsuka America Pharmaceutical, Inc.4$103
Biohaven Pharmaceuticals, Inc.5$97
Medtronic(2 entities)5$96
Tanabe Pharma America, Inc.4$89
Acorda Therapeutics, Inc6$84
Greenwich Biosciences, Inc.3$73
CSL Behring3$62
Livanova USA, Inc.4$61
Aucta Pharmaceuticals, Inc.3$60
Johnson & Johnson(2 entities)3$59
Alnylam Pharmaceuticals Inc.4$56
Microtransponder, Inc.1$47
Aquestive Therapeutics, Inc.2$45
Upsher-smith Laboratories LLC1$32
Mallinckrodt Enterprises LLC1$31
Tonix Medicines, Inc.2$30
Alfasigma USA, Inc.1$24
Cycle Pharmaceuticals Inc1$24
Banner Life Sciences, LLC1$23
Kyowa Kirin, Inc.1$23
Takeda Pharmaceuticals U.S.A., Inc.1$23
Catalyst Pharmaceuticals, Inc.1$20
MDD US Operations, LLC1$20
GE HealthCare1$20
Vanda Pharmaceuticals Inc.1$18
Mallinckrodt Hospital Products Inc.1$16
Aprecia Pharmaceuticals, LLC1$16
Impel Pharmaceuticals Inc.1$16
Biohaven Pharmaceutical Holding Company Ltd.1$14
Zyla Life Sciences, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,360 in reported general payments places this provider in the 65th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$171,683
Medicare patients
349
Services billed
1,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine21$143,683
VumerityDiroximel Fumarate14$110,681
Kesimpta PenOfatumumab11$96,673
BriviactBrivaracetam35$60,263
BotoxOnabotulinumtoxina32$44,264
Lacosamide235$43,898
Nurtec OdtRimegepant Sulfate24$39,476
QuliptaAtogepant20$32,749
RytaryCarbidopa/Levodopa33$29,675
Emgality PenGalcanezumab-Gnlm27$25,408
LamictalLamotrigine17$23,595
XcopriCenobamate19$22,766
KeppraLevetiracetam14$22,318
AptiomEslicarbazepine Acetate16$21,424
Tegretol XrCarbamazepine19$14,294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Nurtec Odt$585$183,16045 claims
BiogenVumerity$1,339$110,68114 claims
AbbVieBotox, Qulipta$1,440$77,01352 claims
UCB, Inc.Briviact$1,595$60,26335 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$378$31,32459 claims
SK Life Science, Inc.Xcopri$1,130$22,76619 claims
Sunovion Pharmaceuticals Inc.Aptiom$251$21,42416 claims
Eisai Inc.Fycompa$355$13,32511 claims
Upsher-smith Laboratories LLCTopiramate$32$1,68386 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 neurology providers in Arizona.

Other neurology in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →